These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30334209)

  • 1. Structure-Based Detection of Orthosteric and Allosteric Pockets at Protein-Protein Interfaces.
    Da Silva F; Rognan D
    Methods Mol Biol; 2018; 1825():281-294. PubMed ID: 30334209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
    Da Silva F; Bret G; Teixeira L; Gonzalez CF; Rognan D
    J Med Chem; 2019 Nov; 62(21):9732-9742. PubMed ID: 31603323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Binding Pockets Versus Allosteric Binding.
    Song K; Zhang J
    Methods Mol Biol; 2018; 1825():295-326. PubMed ID: 30334210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore screening of the protein data bank for specific binding site chemistry.
    Campagna-Slater V; Arrowsmith AG; Zhao Y; Schapira M
    J Chem Inf Model; 2010 Mar; 50(3):358-67. PubMed ID: 20112952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
    Mittal L; Tonk RK; Awasthi A; Asthana S
    Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction.
    Xu Y; Wang S; Hu Q; Gao S; Ma X; Zhang W; Shen Y; Chen F; Lai L; Pei J
    Nucleic Acids Res; 2018 Jul; 46(W1):W374-W379. PubMed ID: 29750256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All in One: Cavity Detection, Druggability Estimate, Cavity-Based Pharmacophore Perception, and Virtual Screening.
    Tran-Nguyen VK; Da Silva F; Bret G; Rognan D
    J Chem Inf Model; 2019 Jan; 59(1):573-585. PubMed ID: 30563339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Druggable orthosteric and allosteric hot spots to target protein-protein interactions.
    Ma B; Nussinov R
    Curr Pharm Des; 2014; 20(8):1293-301. PubMed ID: 23713780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric sites can be identified based on the residue-residue interaction energy difference.
    Ma X; Qi Y; Lai L
    Proteins; 2015 Aug; 83(8):1375-84. PubMed ID: 25185787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Form follows function: shape analysis of protein cavities for receptor-based drug design.
    Weisel M; Proschak E; Kriegl JM; Schneider G
    Proteomics; 2009 Jan; 9(2):451-9. PubMed ID: 19142949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs.
    Jiang L; Zhang X; Chen X; He Y; Qiao L; Zhang Y; Li G; Xiang Y
    Molecules; 2015 Jul; 20(7):12769-86. PubMed ID: 26184151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs.
    Bartuzi D; Kaczor AA; Matosiuk D
    Methods Mol Biol; 2018; 1705():297-319. PubMed ID: 29188568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Computer Vision Approach to Align and Compare Protein Cavities: Application to Fragment-Based Drug Design.
    Eguida M; Rognan D
    J Med Chem; 2020 Jul; 63(13):7127-7142. PubMed ID: 32496770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational method to identify druggable binding sites that target protein-protein interactions.
    Li H; Kasam V; Tautermann CS; Seeliger D; Vaidehi N
    J Chem Inf Model; 2014 May; 54(5):1391-400. PubMed ID: 24762202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motions of Allosteric and Orthosteric Ligand-Binding Sites in Proteins are Highly Correlated.
    Ma X; Meng H; Lai L
    J Chem Inf Model; 2016 Sep; 56(9):1725-33. PubMed ID: 27580047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Computational Methods for the Rational Discovery of Allosteric Drugs.
    Wagner JR; Lee CT; Durrant JD; Malmstrom RD; Feher VA; Amaro RE
    Chem Rev; 2016 Jun; 116(11):6370-90. PubMed ID: 27074285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the Apo Proteins Suitable for the Rational Discovery of Allosteric Drugs?
    An X; Lu S; Song K; Shen Q; Huang M; Yao X; Liu H; Zhang J
    J Chem Inf Model; 2019 Jan; 59(1):597-604. PubMed ID: 30525607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.
    Hui WQ; Cheng Q; Liu TY; Ouyang Q
    J Mol Model; 2016 Apr; 22(4):90. PubMed ID: 27021209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric Modulators of Protein-Protein Interactions (PPIs).
    Ni D; Liu N; Sheng C
    Adv Exp Med Biol; 2019; 1163():313-334. PubMed ID: 31707709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive identification of "druggable" protein ligand binding sites.
    An J; Totrov M; Abagyan R
    Genome Inform; 2004; 15(2):31-41. PubMed ID: 15706489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.